Fate therapeutics announces presentations at the society for immunotherapy of cancer 2021 annual meeting

San diego, oct. 01, 2021 (globe newswire) -- fate therapeutics, inc. (nasdaq: fate), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that one oral and four poster presentations for the company's induced pluripotent stem cell (ipsc) product platform were accepted for presentation at the 36th annual meeting of the society for immunotherapy of cancer (sitc) being held november 10-14, 2021.
FATE Ratings Summary
FATE Quant Ranking